Quotes 5-day view Delayed Nasdaq
06/27/2022
06/28/2022
06/29/2022
06/30/2022
07/01/2022
Date
146.49(c)
142.2(c)
145.43(c)
145.85(c)
148.25(c)
Last
1 198 014
1 716 752
441 019
837 703
568 298
Volume
-0.68% -2.93% +2.27% +0.29% +1.65% Change
Estimated financial data (e) (USD)
Sales 2022
1 089 M - -
Net income 2022
-856 M - -
Net cash position 2022
1 216 M - -
P/E ratio 2022
-21,7x
Yield 2022
-
Sales 2023
1 608 M - -
Net income 2023
-466 M - -
Net cash position 2023
1 283 M - -
P/E ratio 2023
-43,8x
Yield 2023
-
Capitalization
17 911 M 17 911 M -
EV / Sales 2022
15,3x
EV / Sales 2023
10,3x
Nbr of Employees
1 665
Free-Float
99,3%
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It is developing therapeutics based on ribonucleic acid interference (RNAi). Its pipeline includes four products and multiple late and early-stage investigational RNAi therapeutics, that is focused in four strategic therapeutic areas (STArs): Genetic Medicines; Cardio-Metabolic Diseases; Hepatic Infectious Diseases; and CNS/Ocular Diseases. Its RNAi-based...
Ratings of Alnylam Pharmaceuticals, Inc.
All news about ALNYLAM PHARMACEUTICALS, INC.
06/27 EUCOPE Member Spotlight, Q&A with Alnylam AQ
06/27 Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral From Buy MT
06/15 SVB Securities Adjusts Price Target on Alnylam Pharmaceuticals to $98 From $96, Maintai.. MT
06/14 SECTOR UPDATE : Health Care Stocks Finish Above Tuesday's Worst LevelsMT
06/14 SECTOR UPDATE : Health Care Stocks Declining in Tuesday TradingMT
06/14 SECTOR UPDATE : Health Care Stocks Climb Pre-Bell TuesdayMT
06/14 TRANSCRIPT : Alnylam Pharmaceuticals, Inc. - Special CallCI
06/14 ALNYLAM PHARMACEUTICALS : Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi T..PU
06/14 ALNYLAM PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)AQ
06/14 Alnylam Pharmaceuticals Says FDA Approves Amvuttra to Treat Polyneuropathy Caused by Ra.. MT
06/13 Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for.. BU
06/13 Alnylam Announces FDA Approval of AMVUTTRA, an RNAi Therapeutic for the Treatment of th.. CI
06/13 TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 43rd Annual Global He..CI
06/09 TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at 2022 Jefferies Global Healthcare Co..CI
06/09 Alnylam Pharmaceuticals Says Cemdisiran Product Meets Primary Endpoint of Immunoglobuli.. MT
News in other languages on ALNYLAM PHARMACEUTICALS, INC.
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
Pfizer's $11.6 billion Biohaven buy could spark more biotech deals
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
148,25 $
Average target price
204,91 $
Spread / Average Target
38,2%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
